Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
GTx
ClinicalTrials.gov Identifier:
NCT00467844
First received: April 30, 2007
Last updated: June 26, 2014
Last verified: June 2014
Results First Received: January 18, 2013  
Study Type: Interventional
Study Design: Allocation: Randomized;   Endpoint Classification: Efficacy Study;   Intervention Model: Parallel Assignment;   Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor);   Primary Purpose: Supportive Care
Condition: Cachexia
Interventions: Drug: GTx-024
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
GTx -024 1 mg
GTx-024 3 mg
3 mg of Placebo Placebo

Participant Flow:   Overall Study
    GTx -024   GTx-024   3 mg of Placebo
STARTED   53   54   52 
COMPLETED   34   34   38 
NOT COMPLETED   19   20   14 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
GTx -024 1 mg
GTx-024 3 mg
3 mg of Placebo Placebo
Total Total of all reporting groups

Baseline Measures
   GTx -024   GTx-024   3 mg of Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 53   54   52   159 
Age 
[Units: Participants]
       
<=18 years   0   0   0   0 
Between 18 and 65 years   25   22   24   71 
>=65 years   28   32   28   88 
Age 
[Units: Years]
Mean (Standard Deviation)
 65.7  (10.03)   66.3  (10.51)   65.6  (8.73)   65.9  (9.74) 
Gender 
[Units: Participants]
       
Female   19   20   17   56 
Male   34   34   35   103 
Region of Enrollment 
[Units: Participants]
       
United States   39   37   36   112 
Argentina   14   17   16   47 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   The Efficacy of GTx-024 on Total Body Lean Mass.   [ Time Frame: Baseline to Four Months ]

2.  Secondary:   To Assess the Efficacy of GTx-024 on Muscle Function (Performance) as Measured by Stair Climb.   [ Time Frame: Four Months ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats


  More Information